Blar i forfatter "Grønberg, Bjørn Henning"

Viser treff 1-15 av 15

    • Atezolizumab and stereotactic body radiotherapy in patients with advanced non-small cell lung cancer: safety, clinical activity and ctDNA responses—the ComIT-1 trial 

      Horndalsveen, Henrik; Alver, Tine Norman; Dalsgaard, Astrid Marie; Helbekkmo, Nina; Grønberg, Bjørn Henning; Halvorsen, Tarje Onsøien; Ramberg, Christina; Haakensen, Vilde Drageset; Øjlert, Åsa Kristina; Bjaanæs, Maria Moksnes; Helland, Åslaug; Rogg, Lotte Victoria (Journal article; Tidsskriftartikkel; Peer reviewed, 2022-11-04)
      The introduction of immune checkpoint inhibitors has transformed the treatment landscape of metastatic non-small cell lung cancer. However, challenges remain to increase the fraction of patients achieving durable clinical responses to these drugs and to help monitor the treatment effect. In this phase II trial, we investigated the toxicity, systemic responses and circulating tumour DNA responses in ...

    • Comorbidity and outcomes of concurrent chemo- and radiotherapy in limited disease small cell lung cancer 

      Halvorsen, Tarje Onsøien; Sundstrøm, Stein Harald; Fløtten, Øystein; Brustugun, Odd Terje; Brunsvig, Paal Fr.; Aasebø, Ulf; Bremnes, Roy M.; Kaasa, Stein; Grønberg, Bjørn Henning (Journal article; Tidsskriftartikkel; Peer reviewed, 2016-08-23)
      <b>Background:</b> Many patients with limited disease small cell lung cancer (LD SCLC) suffer from comorbidity. Not all patients with comorbidity are offered standard treatment, though there is little evidence for such a policy. The aim of this study was to investigate whether patients with comorbidity had inferior outcomes in a LD SCLC cohort. <br><b>Material and methods:</b> We analyzed patients ...

    • A comparison of CT based measures of skeletal muscle mass and density from the Th4 and L3 levels in patients with advanced non-small-cell lung cancer 

      Grønberg, Bjørn Henning; Sjøblom, Bjørg; Wentzel-Larsen, Tore; Baracos, Vickie Elaine; Hjermstad, Marianne Jensen; Aass, Nina Kathrine; Bremnes, Roy M.; Fløtten, Øystein; Bye, Asta; Jordhøy, Marit Slaaen (Journal article; Tidsskriftartikkel; Peer reviewed, 2018-09-25)
      Background:<br> Muscle mass and density assessed from CT-images at the L3 level are prognostic for survival and predict toxicity in cancer patients. However, L3 is not always included on routine CT-scans. We aimed to investigate whether images at the Th4 level may be used instead. <br> Methods:<br> Patients from three chemotherapy trials in advanced NSCLC were eligible (n = 1305). Skeletal muscle ...

    • Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway 

      Helland, Åslaug; Russnes, Hege Elisabeth Giercksky; Fagereng, Gro Live; Al-Shibli, Khalid Ibrahim; Andersson, Yvonne; Berg, Thomas; Bjørge, Line; Blix, Egil Støre; Bjerkehagen, Bodil; Brabrand, Sigmund; CAMERON, MARTE; Dalhaug, Astrid; Dietzel, Dalia; Dønnem, Tom; Enerly, Espen; Flobak, Åsmund; Fluge, Sverre; Gilje, Bjørnar; Gjertsen, Bjørn Tore; Grønberg, Bjørn Henning; Grønås, Kari; Guren, Tormod Kyrre; Hamre, Hanne Mari; Haug, Åse; Heinrich, Daniel; Hjortland, Geir Olav; Hovig, Eivind; Hovland, Randi; Iversen, Ann-Charlotte; Janssen, Emiel; Kyte, Jon A; Gythfeldt, Hedda; Lothe, Ragnhild Adelheid; Lund, Jo-Åsmund; Meza, Leonardo Zepeda; Munthe-Kaas, Monica Cheng; Nguyen, Olav Toai Duc; Niehusmann, Pitt; Nilsen, Hilde; Puco, Katarina; Ree, Anne Hansen; Riste, Tonje Bøyum; Semb, Karin; Steinskog, Eli Sihn Samdal; Stensvold, Andreas; Suhrke, Pål; Tennøe, Øyvind Krohn; Tjønnfjord, Geir Erland; Vassbotn, Liv Jorunn; Aas, Eline; Aasebø, Kristine Øverås; Tasken, Kjetil; Smeland, Sigbjørn (Journal article; Tidsskriftartikkel; Peer reviewed, 2022-05-14)
      Background: Matching treatment based on tumour molecular characteristics has revolutionized the treatment of some cancers and has given hope to many patients. Although personalized cancer care is an old concept, renewed attention has arisen due to recent advancements in cancer diagnostics including access to high-throughput sequencing of tumour tissue. Targeted therapies interfering with cancer ...

    • Increased expression of individual genes in whole blood is associated with late-stage lung cancer at and close to diagnosis 

      Urbarova, Ilona Halva; Skogholt, Anne Heidi; Sun, Yi-Qian; Mai, Xiao-Mei; Grønberg, Bjørn Henning; Sandanger, Torkjel Manning; Sætrom, Pål; Nøst, Therese Haugdahl (Journal article; Tidsskriftartikkel; Peer reviewed, 2023-11-25)
      Lung cancer (LC) mortality rates are still increasing globally. As survival is linked to stage, there is a need to identify markers for earlier LC diagnosis and individualized treatment. The whole blood transcriptome of LC patients represents a source of potential LC biomarkers. We compared expression of > 60,000 genes in whole blood specimens taken from LC cases at diagnosis (n = 128) and controls ...

    • Increased levels of microRNA-320 in blood serum and plasma is associated with imminent and advanced lung cancer 

      Nøst, Therese Haugdahl; Skogholt, Anne Heidi; Urbarova, Ilona Halva; Mjelle, Robin; Paulsen, Erna-Elise; Dønnem, Tom; Andersen, Sigve; Markaki, Maria; Røe, Oluf Dimitri; Johansson, Mikael; Johansson, Mattias; Grønberg, Bjørn Henning; Sandanger, Torkjel M; Sætrom, Pål (Journal article; Tidsskriftartikkel; Peer reviewed, 2022-11-07)
      Lung cancer (LC) incidence is increasing globally and altered levels of microRNAs (miRNAs) in blood may contribute to identification of individuals with LC. We identified miRNAs differentially expressed in peripheral blood at LC diagnosis and evaluated, in pre-diagnostic blood specimens, how long before diagnosis expression changes of such candidate miRNAs could be detected. We identified upregulated ...

    • Machine learning-based immune phenotypes correlate with STK11/KEAP1 co-mutations and prognosis in resectable NSCLC: a sub-study of the TNM-I trial 

      Rakaee, Mehrdad; Andersen, S.; Giannikou, K.; Paulsen, Erna-Elise; Kilvær, Thomas Karsten; Rasmussen Busund, Lill-Tove; Berg, Thomas; Richardsen, Elin; Lombardi, Ana Paola; Adib, E.; Pedersen, Mona Irene; Tafavvoghi, Masoud; Wahl, Sissel Gyrid Freim; Petersen, R.H.; Bondgaard, A.L.; Yde, C.W.; Baudet, C.; Licht, P.; Lund-Iversen, Marius; Grønberg, Bjørn Henning; Fjellbirkeland, Lars; Helland, Åslaug; Pøhl, M.; Kwiatkowski, D.J.; Dønnem, Tom (Journal article; Tidsskriftartikkel; Peer reviewed, 2023-04-24)
      Background - We aim to implement an immune cell score model in routine clinical practice for resected non-small-cell lung cancer (NSCLC) patients (NCT03299478). Molecular and genomic features associated with immune phenotypes in NSCLC have not been explored in detail.<p> <p>Patients and methods - We developed a machine learning (ML)-based model to classify tumors into one of three categories: ...

    • Muscle mass and association to quality of life in non-small cell lung cancer patients 

      Bye, Asta; Sjøblom, Bjørg; Wentzel-Larsen, Tore; Grønberg, Bjørn Henning; Baracos, Vickie E.; Hjermstad, Marianne Jensen; Aass, Nina Kathrine; Bremnes, Roy M.; Fløtten, Øystein; Jordhøy, Marit Slaaen (Journal article; Tidsskriftartikkel; Peer reviewed, 2017-05-10)
      Background<br> Cancer wasting is characterized by muscle loss and may contribute to fatigue and poor quality of life (QoL). Our aim was to investigate associations between skeletal muscle index (SMI) and skeletal muscle radiodensity (SMD) and selected QoL outcomes in advanced non‐small cell lung cancer (NSCLC) at diagnosis.<p> Methods<br> Baseline data from patients with stage IIIB/IV NSCLC and ...

    • Mutasjonstesting ved ikke-småcellet lungekreft 

      Brustugun, Odd Terje; Helland, Åslaug; Fjellbirkeland, Lars; Kleinberg, Lilach; Ariansen, Sarah Louise; Jebsen, Peter Wilhelm; Scott, Helge; Dønnem, Tom; Bremnes, Roy M.; Berg, Thomas; Grønberg, Bjørn Henning; Dai, Hong Yan; Wahl, Sissel Gyrid Freim; Mangseth, Kjersti; Helgeland, Lars (Journal article; Tidsskriftartikkel; Peer reviewed, 2012-04-30)
      Bakgrunn. Epidermal vekstfaktorreseptor (EGFR) tyrosinkinasehemmere (EGFR-TKI) er en relativt ny klasse legemidler til behandling av ikke-småcellet lungekreft. Den nasjonale faggruppen for lungekreft, Norsk Lunge Cancer Gruppe, anbefaler at pasienter med ikke-småcellet lungekreft testes for mutasjoner i EGFRgenet. Vi rapporterer her erfaringene som er gjort etter at slik testing ble innført i ...

    • The prognostic effect of KRAS mutations in non-small cell lung carcinoma revisited: A norwegian multicentre study 

      Wahl, Sissel Gyrid Freim; Hong, Yan Dai; Emdal, Elisabeth Fritzke; Berg, Thomas; Halvorsen, Tarje Onsøien; Ottestad, Anine Larsen; Lund-Iversen, Marius; Brustugun, Odd; Førde, Dagny; Paulsen, Erna-Elise; Donnem, Tom; Andersen, Sigve; Grønberg, Bjørn Henning; Richardsen, Elin (Journal article; Tidsskriftartikkel; Peer reviewed, 2021-08-26)
      Background: due to emerging therapeutics targeting KRAS G12C and previous reports with conflicting results regarding the prognostic impact of KRAS and KRAS G12C in non-small cell lung cancer (NSCLC), we aimed to investigate the frequency of KRAS mutations and their associations with clinical characteristics and outcome. Since mutation subtypes have different preferences for downstream pathways, we ...

    • Prognostic value of absolute quantification of mutated KRAS in circulating tumour DNA in lung adenocarcinoma patients prior to therapy 

      Wahl, Sissel Gyrid Freim; Hong, Yan Dai; Emdal, Elisabeth Fritzke; Ottestad, Anine Larsen; Dale, Vibeke Grotnes; Richardsen, Elin; Halvorsen, Tarje Onsøien; Grønberg, Bjørn Henning (Journal article; Tidsskriftartikkel; Peer reviewed, 2021-01-27)
      Droplet digital polymerase chain reaction (ddPCR) is a highly sensitive and accurate method for quantification of nucleic acid sequences. We used absolute quantification of mutated v‐Ki‐ras2 Kirsten rat sarcoma viral oncogene homology gene (KRAS) by ddPCR to investigate the prognostic role of mutated KRAS in patients with KRAS‐mutated lung adenocarcinomas. Pre‐treatment plasma samples from 60 patients ...

    • Randomized phase II trial comparing twice daily hyperfractionated with once daily hypofractionated thoracic radiotherapy in limited disease small cell lung cancer 

      Grønberg, Bjørn Henning; Halvorsen, Tarje Onsøien; Fløtten, Øystein; Brustugun, Odd Terje; Brunsvig, Paal Fr.; Aasebø, Ulf; Bremnes, Roy M.; Tollåli, Terje; Hornslien, Kjersti; Aksnessæther, Bjørg Y.; Liaaen, Erik Dyb; Sundstrøm, Stein Harald (Journal article; Tidsskriftartikkel; Peer reviewed, 2015-10-23)
      <br>BACKGROUND: <br> Concurrent chemotherapy and thoracic radiotherapy (TRT) is recommended for limited disease small cell lung cancer (LD SCLC). Twice daily TRT is well documented, but not universally implemented - probably mainly due to inconvenience and concerns about toxicity. A schedule of three-week hypofractionated TRT is a commonly used alternative. This is the first randomized trial ...

    • Survival in Limited Disease Small Cell Lung Cancer According to N3 Lymph Node Involvement 

      Valan, Christine Damgaard; Slagsvold, Jens Erik; Halvorsen, Tarje Onsøien; Herje, Martin; Bremnes, Roy M.; Brunsvig, Paal Fr.; Brustugun, Odd Terje; Fløtten, Øystein; Levin, Nina; Sundstrøm, Stein Harald; Grønberg, Bjørn Henning (Journal article; Tidsskriftartikkel; Peer reviewed, 2018-02)
      Background/Aim: <br>There are several definitions of limited disease (LD) in small cell lung cancer (SCLC), differing with respect to N3 disease accepted. We analyzed patients from a randomized trial comparing two schedules of thoracic radiotherapy (TRT) in LD SCLC to investigate whether there were survival differences between N3 subcategories (n=144). Patients and <br>Methods: <br>Patients ...

    • Tumour size reduction after the first chemotherapy-course and outcomes of chemoradiotherapy in limited disease small-cell lung cancer 

      Halvorsen, Tarje Onsøien; Herje, Martin; Levin, Nina; Bremnes, Roy M.; Brustugun, Odd Terje; Fløtten, Øystein; Kaasa, Stein; Sundstrøm, Stein Harald; Grønberg, Bjørn Henning (Journal article; Tidsskriftartikkel; Peer reviewed, 2016-10-15)
      Objectives: <br> Concurrent chemotherapy and thoracic radiotherapy (TRT) is recommended for limited disease small-cell lung cancer (LD SCLC). TRT should start as early as possible, often meaning with the second course due to patient referral time and the fact that TRT planning takes time. Early assessment of response to the first course of chemotherapy may be a useful way to individualise treatment. ...

    • Vinorelbine and gemcitabine vs vinorelbine and carboplatin as first-line treatment of advanced NSCLC. A phase III randomised controlled trial by the Norwegian Lung Cancer Study Group 

      Fløtten, Øystein; Grønberg, Bjørn Henning; Bremnes, Roy M.; Amundsen, Tore; Sundstrøm, Stein Harald; Rolke, Heidi; HORNSLIEN, KJERSTI; Wentzel-Larsen, Tore; Aasebø, Ulf; von Plessen, Christian (Journal article; Tidsskriftartikkel; Peer reviewed, 2012-07-03)
      BACKGROUND: Platinum-based doublet chemotherapy is the standard first-line treatment for advanced non-small cell lung cancer (NSCLC), but earlier studies have suggested that non-platinum combinations are equally effective and better tolerated. We conducted a national, randomised study to compare a non-platinum with a platinum combination.<p> <p>METHODS: Eligible patients had stage IIIB/IV NSCLC ...